Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough Hopes To Enhance Confidence In Vytorin/Zetia With Monthly Rx Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm feeling impact on sales from Vytorin study results.

You may also be interested in...



Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales

Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.

Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales

Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.

Vytorin, Zetia, Other Combos In Spotlight At ACC Conference

Highlights of the upcoming American College of Cardiology conference include ENHANCE data and updates on ACCOMPLISH and ONTARGET trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS067236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel